Association of matrix metalloproteinase (MMP)-2 and -9 expression with extra-gastrointestinal stromal tumor metastasis

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 10, 2014, Pages 4187-4192

  Wang, Chao ^a   Ma, Hong Xi ^a   Jin, Mei Shan ^a   Zou, Ya Bin ^a   Teng, Yong Liang ^a   Tian, Zhuang ^a   Wang, Hai Ying ^a   Wang, Yin Ping ^a   Duan, Xiu Mei ^a  

^a Basic Medical College   (China)

Author keywords

Biomarker; Extra gastrointestinal stromal tumor (EGIST); MMP 2; MMP 9; Tumor invasion and metastasis

Indexed keywords

GELATINASE A; GELATINASE B; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; BIOSYNTHESIS; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; TUMOR INVASION; UPREGULATION;

ADULT; AGED; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84903538225     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.10.4187     Document Type: Article

References (29)

1. Adler G (2004). Has the biology and treatment of pancreatic diseases evolved? Best Pract Res Clin Gastroenterol, 18, 83-90.
2. Agaimy A, Wunsch PH (2006). Gastrointestinal stromal tumours: a regular origin in the muscularis propria, but an extremely diverse gross presentation. A review of 200 cases to critically re-evaluate the concept of so-called extra-gastrointestinal stromal tumours. Langenbecks Arch Surg, 391, 322-9.
3. Backstrom JR, Tokes ZA (1995). The 84-kDa form of human matrix metalloproteinase-9 degrades substance P and gelatin. J Neurochem, 64, 1312-8.
4. nd (2002). Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann Surg Oncol, 9, 668-74.
5. Cauwe B, Van den Steen PE, Opdenakker G (2007). The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol, 42, 113-85.
6. Dumont N, Bakin AV, Arteaga CL (2003). Autocrine transforming growth factor-beta signaling mediates Smad-independent motility in human cancer cells. J Biol Chem, 278, 3275-85.
7. Espinosa I, Lee CH, Kim MK, et al (2008). A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol, 32, 210-8.
8. Grigioni WF, D'Errico A, Fortunato C, et al (1994). Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane. Mod Pathol, 7, 220-5.
9. Hatfield KJ, Reikvam H, Bruserud O (2010). The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia. Curr Med Chem, 17, 4448-61.
10. Joensuu H (2008). Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol, 39, 1411-9.
11. Kessenbrock K, Plaks V, Werb Z (2010). Matrix metalloproteinases: regulators of the tumor microenvironment. Cell, 141, 52-67.
12. Klein T, Bischoff R (2011). Physiology and pathophysiology of matrix metalloproteases. Amino Acids, 41, 271-90.
13. Labauge P, Brunereau L, Laberge S, Houtteville JP (2001). Prospective follow-up of 33 asymptomatic patients with familial cerebral cavernous malformations. Neurology, 57, 1825-8.
14. Langers AM, Verspaget HW, Hawinkels LJ, et al (2012). MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients. Br J Cancer, 106, 1495-8.
15. Levy AT, Cioce V, Sobel ME, et al (1991). Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res, 51, 439-44.
16. Liu Z, Li L, Yang Z, et al (2010). Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer, 10, 270.
17. Reith JD, Goldblum JR, Lyles RH, Weiss SW (2000). Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol, 13, 577-85.
18. Ring P, Johansson K, Hoyhtya M, Rubin K, Lindmark G (1997). Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer-a predictor of tumour stage. Br J Cancer, 76, 805-11.
19. Rodriguez D, Morrison CJ, Overall CM (2010). Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta, 1803, 39-54.
20. Roy R, Yang J, Moses MA (2009). Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol, 27, 5287-97.
21. Sier CF, Kubben FJ, Ganesh S, et al (1996). Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer, 74, 413-7.
22. Wang C, Jin MS, Zou YB, et al (2013). Diagnostic significance of DOG-1 and PKC-theta expression and c-Kit/PDGFRA mutations in gastrointestinal stromal tumours. Scand J Gastroenterol, 48, 1055-65.
23. West RB, Corless CL, Chen X, et al (2004). The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol, 165, 107-13.
24. Yadav L, Puri N, Rastogi V, Satpute P, Ahmad R, Kaur G (2014). Matrix metalloproteinases and cancer-roles in threat and therapy. Asian Pac J Cancer Prev, 15, 1085-91.
25. Yamamoto H, Oda Y, Kawaguchi K, et al (2004). c-kit and PDGFRA mutations in extragastrointestinal stromal tumor (gastrointestinal stromal tumor of the soft tissue). Am J Surg Pathol, 28, 479-88.
26. Yuan Y, Zhang W, Yan R, et al (2009). Identification of a novel 14-3-3zeta binding site within the cytoplasmic domain of platelet glycoprotein Ibalpha that plays a key role in regulating the von Willebrand factor binding function of glycoprotein Ib-IX. Circ Res, 105, 1177-85.
27. Yukawa N, Yoshikawa T, Akaike M, et al (2001). Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinoma. Br J Surg, 88, 1596-601.
28. Zeng ZS, Huang Y, Cohen AM, Guillem JG (1996). Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol, 14, 3133-40.
29. Zhang S, Li L, Lin JY, Lin H (2003). Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol, 9, 899-904.